Tarsus Pharmaceuticals, Inc. TARS Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -9.5%+6.2pp | -15.7%+8.2pp | -23.9%+9.3pp | -33.2%+13.5pp | -46.7%+19.2pp | |
| Net margin | -9%+5.7pp | -14.7%+7.5pp | -22.2%+9.0pp | -31.1%+13.8pp | -44.9%+18.3pp | |
| EBITDA margin | -9.2%+6.2pp | -15.3%+8.1pp | -23.4%+9.2pp | -32.6%+13.5pp | -46.1%+19.1pp | |
| Returns | ||||||
| Return on equity | -14%+9.4pp | -23.4%+5.0pp | -28.3%+3.1pp | -31.5%+2.5pp | -34%+20.8pp | |
| Return on assets | -8.9%+5.2pp | -14.1%+3.7pp | -17.8%+3.3pp | -21.1%+3.6pp | -24.7%+11.3pp | |
| Return on invested capital | -17.8%+14.4pp | -32.3%+7.7pp | -40%+3.5pp | -43.5%+18.8pp | -62.4%+56.2pp | |
| Efficiency | ||||||
| Asset turnover | 1×0.0× | 1×+0.2× | 0.8×+0.1× | 0.7×+0.1× | 0.5×0.0× | |
| Liquidity | ||||||
| Current ratio | 3.7×-0.1× | 3.9×-0.4× | 4.3×-1.0× | 5.3×-0.3× | 5.6×+1.1× | |
| Quick ratio | 3.7×-0.1× | 3.8×-0.4× | 4.3×-1.0× | 5.2×-0.3× | 5.5×+1.1× | |
| Cash ratio | 0.7×-0.6× | 1.4×+0.4× | 1×-0.1× | 1.1×-1.0× | 2.1×+0.9× | |
| Leverage | ||||||
| Debt-to-equity | 0.3×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×-0.1× | |
| Debt-to-assets | 0.2×0.0× | 0.1×0.0× | 0.2×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Interest coverage | -5.7×+2.2× | -7.9×+1.7× | -9.7×+1.0× | -10.6×+1.4× | -12×+3.3× | |
| Per Share | ||||||
| Book value per share | $8.12-1.2% | $8.22+4.5% | $7.86+0.2% | $7.85-9.8% | $8.70+45.8% | |
| Valuation | ||||||
| Market capitalization | $2.99B-14.1% | $3.48B+38.5% | $2.51B+44.2% | $1.74B-17.8% | $2.12B0.0% | |
| Enterprise value | $2.97B-11.9% | $3.37B+36.2% | $2.48B+44.6% | $1.71B-14.8% | $2.01B-3.9% | |
| Price / sales | 5.6×-2.1× | 7.7×+0.8× | 6.9×+1.0× | 5.9×-3.2× | 9.1×-2.5× | |
| Price / book | 8.6×-1.6× | 10.1×+2.6× | 7.5×+2.3× | 5.2×-0.9× | 6.2×-3.2× | |
| EV / sales | 5.6×-1.9× | 7.5×+0.7× | 6.8×+1.0× | 5.8×-2.8× | 8.6×-2.8× | |
| Earnings yield | -1.6%+0.3pp | -1.9%+1.3pp | -3.2%+2.1pp | -5.3%-0.3pp | -5%+0.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Tarsus Pharmaceuticals, Inc.'s profit margins?
- Tarsus Pharmaceuticals, Inc. (TARS) runs a 42.7% gross margin and a -9.5% operating margin, with a -9.0% net margin.
- Where do Tarsus Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Tarsus Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
